Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe
Teva has emerged as the winner in a months-long bidding war for ratiopharm, Germany's second-largest generics manufacturer after Novartis's Sandoz unit
You may also be interested in...
Positive opinions from Europe's top drug assessment panel in May have included a long-acting "biobetter" lipegfilgrastim from Teva, a once-weekly HGH injection from Biopartners GmbH, and a smallpox vaccine developed by Bavarian Nordic with funding from the U.S. BioShield program.
Teva Pharmaceutical Industries Ltd. announced May 16 that it is acquiring more than half of Japan's third largest generic drugmaker and extending an offer to purchase the remaining portion of the company
The world's largest maker of generic drugs buys access to the rapidly growing Japanese generics market with the acquisition of Taiyo Pharmaceuticals.